|
V11781
|
AT-1001 |
881851-50-9 |
AT-1001, formerly known as Larazotide Acetate, is a novel and synthetic peptide acting as a tight junction regulator and reverses leaky junctions to their normally closed state. |
|
V77236
|
AT-1002 TFA |
|
AT-1002 TFA is a 6-mer synthetic peptide, a tight junction regulator and absorption enhancer. |
|
V21513
|
Danegaptide (GAP-134) hydrochloride |
943133-81-1 |
Danegaptide hydrochloride (GAP-134 and ZP-1609) is a novel,potent, selective andorally bioavailable small molecule gap-junction modifier with a potentialfor thetreatment of atrial fibrillation. |
|
V31985
|
Gap 26 |
197250-15-0 |
Gap 26 is a connexin (connexin) mimetic peptide, consisting of residues 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), and contains the SHVR amino acid (AA) motif. |
|
V76988
|
Gap 26 TFA |
|
Gap 26 TFA is a connexin (connexin) mimetic peptide, consisting of residues 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), and contains the SHVR amino acid (AA) motif. |
|
V31969
|
Gap 27 |
198284-64-9 |
Gap 27, a synthetic connexin43 mimetic peptide, is a gap junction inhibitor. |
|
V41018
|
Peptide5 |
916977-43-0 |
Peptide5, a mimetic peptide of connexin 43, reduces swelling, astrogliosis, and neuronal cell death in animals after spinal cord injury. |
|
V76639
|
Peptide5 TFA |
|
Peptide5 TFA, a mimetic peptide of connexin 43, reduces swelling, astrogliosis, and neuronal cell death in animals after spinal cord injury. |
|
V55719
|
TAT-Gap19 |
1507930-54-2 |
TAT-Gap19 is a Cx mimetic peptide and a specific connexin43 hemichannel (Cx43 HC) inhibitor. |
|
V76451
|
TAT-Gap19 TFA |
|
TAT-Gap19 TFA is a Cx mimetic peptide and a specific connexin43 hemichannel (Cx43 HC) inhibitor. |
|
V4626
|
Tonabersat (SB220453) |
175013-84-0 |
Tonabersat (also known as SB-220453), a benzopyran derivative, is a novel and potent gap-junction modulator used for the prevention of migraine. |